BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33953346)

  • 1. Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Friend T; Stebbing J
    Br J Cancer; 2021 Sep; 125(7):907-908. PubMed ID: 33953346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
    Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Examination of molecular markers used n the treatment of colon cancer].
    Domagała P; Kowalik A
    Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation.
    Sun Q; Liu Y; Liu B; Liu Y
    Am J Med Sci; 2018 Mar; 355(3):220-227. PubMed ID: 29549923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
    Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
    Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
    Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A French point of view about the cost effectiveness of RASQ61R immunohistochemistry in colorectal cancer.
    Uguen A
    Pathology; 2017 Dec; 49(7):810-811. PubMed ID: 29061330
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
    Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
    PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
    Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
    Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
    Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
    Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
    Bylsma LC; Gillezeau C; Garawin TA; Kelsh MA; Fryzek JP; Sangaré L; Lowe KA
    Cancer Med; 2020 Feb; 9(3):1044-1057. PubMed ID: 31856410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma.
    Vittal A; Sharma D; Samanta I; Kasi A
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31519714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
    Grothey A; Sargent DJ
    JAMA Oncol; 2016 Sep; 2(9):1133-4. PubMed ID: 27273467
    [No Abstract]   [Full Text] [Related]  

  • 20. Tri-modal liquid biopsy: Combinational analysis of circulating tumor cells, exosomes, and cell-free DNA using machine learning algorithm.
    Bu J; Lee TH; Poellmann MJ; Rawding PA; Jeong WJ; Hong RS; Hyun SH; Eun HS; Hong S
    Clin Transl Med; 2021 Aug; 11(8):e499. PubMed ID: 34459134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.